Investor profile
Bioqube Ventures
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Bioqube Ventures is a Europe-rooted VC with global reach, focused exclusively on therapeutics. The firm backs bold science and builds enduring companies, investing in first- or best-in-class therapeutics to address major unmet medical needs. Being stage-agnostic, Bioqube builds balanced portfolios supporting companies from inception through early clinical milestones — acting not just as investors but as scientists, operators, and builders who help structure, scale, and stand by their companies all the way. Founded in 2015 and launched on the Janssen Pharmaceutica R&D campus in Belgium, Bioqube has backed and supported over 20 biotech companies. With the launch of the Bioqube Factory Funds in 2020, the firm expanded its reach across Europe (with a focus on Benelux, France, and Germany), the United States, and the rest of the world. Strategic partners include Johnson & Johnson Innovation – JJDC, Genmab, and IQVIA, blending scientific insight and financial strength to turn breakthrough science into lasting impact.
Notable quotes
“We are excited to join the SynOx syndicate and work with this fantastic team and board. We believe this asset has the potential to generate best-in-class data and are excited to help the team develop the product through approval and launch.”
“Bioqube Factory Fund I will aim to invest in two key areas: 'classical' early-stage biotech deals, and assets or projects that require additional de-risking in order to progress to the next stage.”
“We are thrilled to co-lead this financing and join the CatalYm board. The data generated to date with visugromab is truly impressive and we are excited to support the team as they advance this program through a broad Phase 2b development program.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Primmune Therapeutics | Series B | $9m | 2026-01-26 |
| Actithera | Series A | $76m | 2025-07-09 |
| Spica Therapeutics | Seed | $11m | 2025-06-03 |
| CatalYm | Series D | $150m | 2024-07-16 |
| SynOx Therapeutics | Series B | $75m | 2024-04-22 |
| Bicara Therapeutics | Series B | $108m | 2023-01-01 |
| Egle Therapeutics | Series A | — | 2021-10-22 |
| Commit Biologics | Seed | — | 2023-05-02 |
| Anavo Therapeutics | Series A | — | 2024-07-15 |
| Enhanc3D Genomics | Seed | — | 2021-03-26 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| Forbion | 3 |
| Omega Funds | 3 |
| Gilde Healthcare | 2 |
| HealthCap | 2 |
| Sofinnova Partners | 2 |
| Johnson & Johnson Innovation – JJDC | 2 |
Fit check
Is Bioqube Ventures a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit